Articles tagged with Alzheimer Disease
Researchers developed a method to differentiate patients with Alzheimer's disease from those with other types of dementia using biomarkers in cerebrospinal fluid. The study analyzed five proteins and found that they could accurately diagnose Alzheimer's disease, as well as distinguish it from Parkinson's disease and Lewy body dementia.
A new study found a connection between Alzheimer's disease and the activity level of eIF2alpha protein. Researchers believe altering this protein via drug therapy could lead to a treatment for the incurable disease.
A $5.4 million grant from the Cure Alzheimer's Fund will support state-of-the-art whole genome DNA sequencing to better understand Alzheimer's disease genetics. The research aims to identify genetic switches controlling the disease, with findings made freely available to the scientific community.
Researchers have made significant progress in developing new diagnostic tools and treatments for Alzheimer's disease. Changes in brain function can be detected years before symptoms appear, using PET scans, and a new antibody probe could lead to an early detection test.
A study found that high beta amyloid plaque levels associated with Alzheimer's disease can lead to steeper memory decline in healthy older individuals. The research used PET brain scans and cognitive assessments to track participants over a year and a half, revealing a significant correlation between plaque accumulation and memory loss.
Researchers at Washington State University have developed a new drug candidate that improves cognitive function in rats with Alzheimer's-like mental impairment by building new brain cell connections. The compound, called Dihexa, is stable and can cross the blood-brain barrier, allowing for pill-form administration.
Researchers found that reducing perceptual interference can improve object perception in individuals with mild cognitive impairment (MCI) and early-stage Alzheimer's disease. The study suggests that minimizing visual clutter could help MCI patients with everyday tasks, such as recognizing familiar faces and objects.
Researchers created a mouse model reproducing Alzheimer's chemical changes to shed light on spatial memory issues. The study found reduced acetylcholine led to spatial memory deficits and hyperactivity in mice.
Researchers at Gladstone Institutes discover how a protein deficiency contributes to neurodegenerative disease frontotemporal dementia (FTD). Progranulin prevents microglia from becoming hyperactive, leading to inflammation that destroys neurons and causes debilitating symptoms.
Researchers led by CSIC and Kiel University reveal meprin β, an enzyme anchored in cell walls that cuts off proteins. The study found a dimeric structure with a cleft that acts as the scissor-like active site.
Scientists have discovered a promising approach to combatting Alzheimer's disease by countering neuroinflammation. A new compound has shown efficacy comparable to an existing medicine in relieving nerve inflammation and improving learning and memory.
A recent study found that low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer's disease in men, but not women. IGF-1 may be a potential treatment target for early-stage Alzheimer's disease.
A new study from Georgia Tech and the University of Toronto found that reducing visual clutter can improve object perception in individuals with mild cognitive impairment. The researchers tested MCI patients on identifying identical pairings, finding that interspersing similar objects with dissimilar ones reduced interference.
Researchers found that combining daily melatonin intake with voluntary physical exercise had a significant regressing effect on Alzheimer's disease in rodents. The study showed improved behavior, learning, and memory, as well as reduced oxidative stress and amyloid beta peptide levels.
A Tel Aviv University researcher is using fruit flies to study the functioning of neurons and potential treatments for Alzheimer's disease. By genetically modifying flies to express a protein linked to human Alzheimer's, she hopes to unlock its function and develop new therapies.
Researchers discovered that EGFR inhibitors and synthetic compounds can reverse memory loss in fruit fly and mouse models of Alzheimer's disease. The study suggests blocking EGFR signaling prevents memory loss by preventing beta-amyloid proteins from activating the receptor.
Researchers have discovered how chemical agents bind to and detect amyloid beta plaques and tau tangles in the brain, enabling quicker diagnosis and earlier treatment. The study's findings will speed the development of new imaging agents, providing potential benefits for patients with early Alzheimer's disease.
Manuela Neumann has been recognized with a Euro 150,000 award from the French Alzheimer's Foundation for her groundbreaking research on abnormal proteins in neurodegenerative diseases. The award aims to support further investigations into mechanisms and causes of these diseases.
Researchers at Mayo Clinic discovered a new enzyme called BACE2 that destroys beta-amyloid, a toxic protein fragment associated with Alzheimer's disease. The discovery suggests that impairments in BACE2 may increase the risk of Alzheimer's disease and could lead to gene therapy as a potential treatment.
Researchers at the University of Pennsylvania School of Medicine have found that surgery itself has a profound impact on brain pathology and cognition in mice with human Alzheimer disease genes. Surgery causes a lasting increase in Alzheimer's pathology and significant cognitive impairment, primarily through inflammation.
A recent study identified a gene linking age-related cataracts and Alzheimer's disease, suggesting common etiologic factors between the two conditions. The study found correlations between cortical cataract formation and brain degeneration measures, as well as poorer cognitive performance.
A Concordia University study has found that adults with mild cognitive impairment (MCI) are impaired in several aspects of executive functioning, particularly inhibitory control. The researchers hope their work will lead to the development of more reliable tools for detecting Alzheimer's disease at an earlier stage.
A consensus document developed by leading Alzheimer's researchers, advocates, and clinicians provides prioritized goals for the nation's healthcare system. The plan aims to advance understanding of the disease, develop effective treatments, and integrate healthcare and social services.
The California Institute for Regenerative Medicine awards UC Irvine $5.6 million for Alzheimer's research, while Dr. Henry Klassen receives $17.3 million to develop stem cells for retinitis pigmentosa treatment. Researchers aim to advance human clinical trials using stem cells to improve memory in people with Alzheimer's disease.
Researchers found that sleep disturbances occur when Alzheimer's plaques appear in the brain, disrupting the normal sleep-wake cycle. The study suggests that sleep problems could be an easily detectable sign of pathology, potentially indicating whether new treatments are succeeding.
A five-year randomized controlled trial of 2854 elderly patients found no significant difference between ginkgo biloba extract and placebo in preventing Alzheimer's disease diagnosis. No significant difference was also observed in mortality or stroke rates between the groups. The results confirm previous findings from a US-based study.
New research reveals professional football players are three times more likely to die from brain-damaging diseases compared to the general population. The study found a significant increase in deaths from Alzheimer's disease and ALS among speed position players, highlighting potential risks of chronic traumatic encephalopathy (CTE).
Researchers found that eliminating an enzyme called jnk3 leads to a 90% reduction in amyloid beta peptides, a hallmark of Alzheimer's disease. This finding suggests jk3 could be a new target for Alzheimer's intervention.
Researchers at Cleveland Clinic's Lerner Research Institute and Anesthesiology Institute have discovered a potential new treatment for Alzheimer's disease. The compound MDA7 has been shown to induce beneficial immune responses that limit the development of the disease, restoring cognition, memory, and synaptic plasticity in animal models.
Abnormalities in mitochondrial length promote neurodegenerative diseases like Alzheimer's, while optimal length is essential for maintaining cellular health. The study reveals a complex interplay between proteins DRP1 and actin, which are affected by defective tau protein.
Researchers found that Alzheimer's protein APP is related to the production of neurotransmitters and can curb their creation. The study suggests a new mechanism by which abnormal APP deposits in Alzheimer's patients disrupt nerve cell signaling.
Researchers at Sanford-Burnham Medical Research Institute discovered that BACE1 disrupts cellular processes required for PKA function, leading to impaired learning and memory. This finding suggests that targeting BACE1 expression in the brain could be a potential therapy for Alzheimer's disease and age-related memory loss.
Patients with Alzheimer's who suffered delirium episodes had a sharply increased rate of mental decline for up to five years after hospitalization compared to those without episodes. The study highlights the importance of recognizing and preventing delirium, which is estimated to cost the healthcare system billions annually.
Researchers identified a group of elderly people with exceptional memories and brains that resemble those of middle-aged individuals. Their cortex thickness and attention region were found to be thicker than normal aging peers, suggesting a greater number of neurons and potentially improved cognitive abilities.
Researchers found that high baseline levels of neuronal activity in key brain regions may contribute to Alzheimer's development. The study suggests that brain dynamics could play a causal role in the disease.
Researchers at the University of Rochester Medical Center have discovered a new brain cleaning system called the glymphatic system, which acts like a shadow plumbing system to drain away waste products from the brain. The system is highly organized and operates on a much larger scale than previously thought.
Latrepirdine, a compound initially rejected for Alzheimer's treatment, shows promise in animal models by reducing neurodegeneration-related proteins and activating autophagy. The study suggests potential benefits in treating or preventing disorders associated with high levels of alpha-synuclein.
Scientists have identified a group of blood markers that show consistent findings in patients with Alzheimer's disease and mild cognitive impairment. The study found four proteins that correlated with beta-amyloid levels in cerebrospinal fluid, providing potential clues for an early diagnosis.
Research on Alzheimer's disease is gaining momentum, with over 150 companies working on innovative approaches to tackle the debilitating disease. New therapies, such as Antisenilin and Gammagard, are in Phase III trials and show promise in addressing the underlying biology of the disease.
Researchers at Gladstone Institutes found that levetiracetam, an FDA-approved anti-epileptic drug, reverses memory loss and alleviates other Alzheimer's-related impairments in mice genetically modified to simulate key aspects of the disease. The study shows how levetiracetam suppresses abnormal brain activity and restores memory function.
Researchers found that younger elderly (60s-70s) show faster rates of brain tissue loss and cognitive decline than older AD patients. This discovery has profound implications for diagnosing AD and finding new treatments.
Researchers at Stanford Medicine discovered that A-beta, a molecule linked to Alzheimer's disease, reverses paralysis and inflammation in mouse models of multiple sclerosis. The findings suggest potential new treatments for the autoimmune disease.
A new study finds that diacetyl intensifies the damaging effects of abnormal brain protein linked to Alzheimer's disease. Chronic exposure to diacetyl has also been shown to enhance beta-amyloid toxicity on nerve cells, raising concerns over long-term neurological toxicity.
Research suggests autoantibodies contribute to blood vessel damage in the brain, exacerbating Alzheimer's and vascular dementia. Immunoadsorption therapy has shown promise in improving symptoms in patients with Alzheimer's disease.
A study published by researchers at Mount Sinai School of Medicine suggests that latrepirdine, a previously failed Alzheimer's drug, may be successful if tested on patients with earlier stages of the disease. The compound effectively stopped progression of memory deterioration and brain pathology in mouse models.
The American Health Assistance Foundation has awarded grants to scientists worldwide studying the link between Alzheimer's disease and glaucoma, as well as protective mechanisms for eye cells. Researchers are also developing new treatments for macular degeneration, a condition causing vision loss in older adults.
A study by Tufts University researchers found that a single moderate-to-severe traumatic brain injury can disrupt proteins regulating BACE1 enzyme associated with Alzheimer's. The team identified complex mechanisms leading to rapid elevation of BACE1 in the brain, which may lead to new drug treatment targeting this mechanism.
A new class of drug developed at Northwestern University has shown early promise in reducing inflammation in the brain, which is a common denominator in these neurological diseases. The drug targets proinflammatory cytokines and prevents their overproduction, preventing damage to synapses and neurons.
Experts from NYU Langone Medical Center will present research on non-invasive evaluation of tau targeted immunotherapy, physician intention to screen for dementia, and remission of pre-mild cognitive impairment. These studies aim to improve diagnosis and treatment of Alzheimer's disease.
Researchers at Brigham and Women's Hospital are conducting a new study, REVEAL, which will provide genetic testing and Alzheimer's risk estimates for individuals with mild cognitive impairment. The goal is to evaluate how well participants understand the risk information and adjust their behavior in response.
An anti-tau treatment called epithilone D (EpoD) has shown promise in preventing and intervening the progress of Alzheimer's disease in animal models by improving neuron function and cognition. The drug aims to stabilize microtubules, which support the transport of essential nutrients and information between cells.
A study found that people with metabolic syndrome, a combination of heart disease and type 2 diabetes risk factors, have 15% less blood flow to the brain than those without the condition. This could lead to reduced memory skills, but it is unclear if it will increase the risk of Alzheimer's disease.
Researchers found that caregivers who believe people with Alzheimer's disease are at risk for injury and accept help more likely rely on dependency support rather than promoting independence. Caregivers can learn to gauge individual abilities through observation, breaking down tasks into manageable activities.
Researchers at the Mayo Clinic found that slow gait and short stride are associated with an increased risk of cognitive decline. The study measured over 1,300 participants and found significant declines in global cognition, memory, and executive function among those with lower cadence and velocity.
A new study found that higher levels of ceramides in the blood are associated with a 10-fold increased risk of developing Alzheimer's disease. The research suggests that identifying this biomarker could help prevent or delay the disease, which is expected to double globally every 20 years.
Experts warn that revealing biomarker results to asymptomatic individuals can cause anxiety and depression, while safeguards are needed to prevent marginalization or mistreatment. The prevention trial aims to better understand how older adults make sense of risk information and its impact on health and well-being.
Researchers at Albert Einstein College of Medicine found that individuals with amnestic mild cognitive impairment have twice the risk of dying compared to cognitively normal people. The study, which followed 733 participants over five years, also found a threefold increase in mortality risk for those with dementia.
A team of scientists at the New York Stem Cell Foundation developed a cell-based model of Alzheimer's disease by reprogramming skin cells from patients into brain cells that are affected in Alzheimer's. The model recapitulates the features and functions of patient suffering from Alzheimer's, providing a critical tool for future researc...
Researchers mapped brain activity in 892 cognitively normal individuals and found that Alzheimer's patients spend more time using certain roads and less time with others. This suggests that varying brain activity may reduce the risk of Alzheimer's disease, potentially through activities like exercise, education, and social connections.
The American Health Assistance Foundation (AHAF) has awarded 22 new research grants to scientists studying innovative approaches to combat Alzheimer's disease, including repurposing existing drugs and examining the link between diabetes and cognitive decline.